Abstract

The E3 ubiquitin protein UBR5 has been implicated in the regulation of multiple biological functions and has recently emerged as a key regulator of the ubiquitin-proteasome system (UPS) in cancer. However, the clinical significance and biological function of UBR5 in colorectal cancer (CRC) are poorly understood. In this study, we compared the expression pattern of UBR5 between CRC and adjacent normal tissues and found that UBR5 expression was frequently elevated in CRC, possibly through chromosomal gains. Using three CRC patient cohorts, we found that patients with high UBR5 mRNA levels, UBR5 gene amplification, or high nuclear UBR5 protein levels had poor prognoses. Multivariate analysis showed that the alterations in UBR5 were independent predictors of CRC prognosis with the TNM stage as a confounding factor. Furthermore, knockdown of UBR5 prevented the proliferation, colony formation, migration, and invasion of CRC cells in cell culture models. An in vivo animal model further confirmed that UBR5 knockdown reduced the growth of CRC tumors. In conclusion, our study is the first to systematically investigate the clinical and biological significance of UBR5 and to conclude that an elevated UBR5 level plays an oncogenic role and may be a potential prognostic marker in CRC.

Highlights

  • Colorectal cancer (CRC) is one of the most common and lethal malignancies, with approximately one million new cases diagnosed annually worldwide [1]

  • Because changes in mRNA expression could be caused by somatic copy number variations (CNVs), we investigated the association between the UBR5 mRNA levels and the corresponding copy numbers of the gene

  • In the gene-dosage analysis, significant positive correlations were found between the UBR5 gene copies and the UBR5 mRNA levels measured by RNA-seq (n = 376, R2 = 0.436, P < 0.001) or Agilent array (n = 217, R2 = 0.380, P < 0.001), which indicated that copy number gains might be an important contributor to the elevated UBR5 expression in colorectal cancer (CRC) (Figure 1C)

Read more

Summary

Introduction

Colorectal cancer (CRC) is one of the most common and lethal malignancies, with approximately one million new cases diagnosed annually worldwide [1]. Among these CRC cases, approximately 14-25% are accompanied by distant metastasis [2], which usually results in a poor prognosis. Pathological staging remains the most reliable method for the prognostic stratification of CRC patients and the selection of neo-adjuvant treatments [4, 6], but this method is imperfect and its prognostic value has been recently challenged [7]. More effective biomarkers are needed for people to predict CRC prognosis and to perform treatment stratification

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call